Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF

A pilot study

Mamidipudi Srinivasa Vidyasagar, Maheedhar Kodali, Prathima N. Balu, Gunjan Baijal, Bejadi Manjunath Vadhiraja, Rani A. Bhat, Donald Jerard Fernandes, Chilakapati Murali Krishna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Exploration of the feasibility of serum protein profiles for monitoring tumor radioresponse in cervical cancers using HPLC-LIF system. Materials and methods: Twenty-one subjects were recruited in the study. Out of them 7 were healthy, 14 were cervical cancer patients who undertook fractionated radiotherapy (RT) with 2 Gy per fraction over 25 fractions, for 5 weeks followed by 2 applications of intracavitary brachytherapy once a week. Blood collected from above subjects was processed to obtain serum. Serum chromatograms of 'normal' (n=7) and conspicuous probes before RT (n=14, 'malignant') and 24 h after second fraction of RT (n=13, '2-RT'), were recorded using an In-house-built HPLC-LIF set-up. Data were analyzed in two approaches: (1) classical method using relative intensities of selected peaks, (2) principal component analysis (PCA). Clinical assessment of tumor radioresponse was carried out 4 months after first fraction of RT and the degree of the tumor shrinkage was determined as an index of radioresponsiveness (complete response (CR): 100% shrinkage, partial response (PR): ≥50% shrinkage, and no response (NR): ≤50% shrinkage) which was further correlated with the analysis of 2-RT serum chromatograms. Results: Normal vs. malignant chromatograms demonstrated pronounced differences in the 800-1800 s region. Malignant vs. 2-RT chromatograms showed minute variations in the 1300-1800 s region. Our analysis, in both of the approaches, produced clear differentiation between 'normal' and 'malignant', whereas differentiation between 'malignant' and '2-RT' was minimal. Clinical evaluation of the tumor radioresponse yielded that out of 13 patients (one patient discontinued the radiotherapy) ten showed CR, two showed PR and one NR. In case of prediction of tumor radioresponse, analysis of the 2-RT chromatograms produced only minor differentiation among CR, PR and NR groups. Conclusion: Protein profiling of serum samples differentiated 'normal' from 'malignant', but could not differentiate 'malignant' from '2-RT'. Also this technique has limited application in prediction of tumor radioresponse.

Original languageEnglish
Pages (from-to)165-174
Number of pages10
JournalMedical Laser Application
Volume24
Issue number3
DOIs
Publication statusPublished - 01-08-2009

Fingerprint

Uterine Cervical Neoplasms
Blood Proteins
Radiotherapy
High Pressure Liquid Chromatography
Neoplasms
Serum
Brachytherapy
Principal Component Analysis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Dermatology

Cite this

Vidyasagar, M. S., Kodali, M., Balu, P. N., Baijal, G., Vadhiraja, B. M., Bhat, R. A., ... Krishna, C. M. (2009). Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF: A pilot study. Medical Laser Application, 24(3), 165-174. https://doi.org/10.1016/j.mla.2009.05.005
Vidyasagar, Mamidipudi Srinivasa ; Kodali, Maheedhar ; Balu, Prathima N. ; Baijal, Gunjan ; Vadhiraja, Bejadi Manjunath ; Bhat, Rani A. ; Fernandes, Donald Jerard ; Krishna, Chilakapati Murali. / Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF : A pilot study. In: Medical Laser Application. 2009 ; Vol. 24, No. 3. pp. 165-174.
@article{5442199854fb49fd8870c30552abe58d,
title = "Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF: A pilot study",
abstract = "Objective: Exploration of the feasibility of serum protein profiles for monitoring tumor radioresponse in cervical cancers using HPLC-LIF system. Materials and methods: Twenty-one subjects were recruited in the study. Out of them 7 were healthy, 14 were cervical cancer patients who undertook fractionated radiotherapy (RT) with 2 Gy per fraction over 25 fractions, for 5 weeks followed by 2 applications of intracavitary brachytherapy once a week. Blood collected from above subjects was processed to obtain serum. Serum chromatograms of 'normal' (n=7) and conspicuous probes before RT (n=14, 'malignant') and 24 h after second fraction of RT (n=13, '2-RT'), were recorded using an In-house-built HPLC-LIF set-up. Data were analyzed in two approaches: (1) classical method using relative intensities of selected peaks, (2) principal component analysis (PCA). Clinical assessment of tumor radioresponse was carried out 4 months after first fraction of RT and the degree of the tumor shrinkage was determined as an index of radioresponsiveness (complete response (CR): 100{\%} shrinkage, partial response (PR): ≥50{\%} shrinkage, and no response (NR): ≤50{\%} shrinkage) which was further correlated with the analysis of 2-RT serum chromatograms. Results: Normal vs. malignant chromatograms demonstrated pronounced differences in the 800-1800 s region. Malignant vs. 2-RT chromatograms showed minute variations in the 1300-1800 s region. Our analysis, in both of the approaches, produced clear differentiation between 'normal' and 'malignant', whereas differentiation between 'malignant' and '2-RT' was minimal. Clinical evaluation of the tumor radioresponse yielded that out of 13 patients (one patient discontinued the radiotherapy) ten showed CR, two showed PR and one NR. In case of prediction of tumor radioresponse, analysis of the 2-RT chromatograms produced only minor differentiation among CR, PR and NR groups. Conclusion: Protein profiling of serum samples differentiated 'normal' from 'malignant', but could not differentiate 'malignant' from '2-RT'. Also this technique has limited application in prediction of tumor radioresponse.",
author = "Vidyasagar, {Mamidipudi Srinivasa} and Maheedhar Kodali and Balu, {Prathima N.} and Gunjan Baijal and Vadhiraja, {Bejadi Manjunath} and Bhat, {Rani A.} and Fernandes, {Donald Jerard} and Krishna, {Chilakapati Murali}",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.mla.2009.05.005",
language = "English",
volume = "24",
pages = "165--174",
journal = "Medical Photonics",
issn = "1615-1615",
publisher = "Elsevier GmbH",
number = "3",

}

Vidyasagar, MS, Kodali, M, Balu, PN, Baijal, G, Vadhiraja, BM, Bhat, RA, Fernandes, DJ & Krishna, CM 2009, 'Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF: A pilot study', Medical Laser Application, vol. 24, no. 3, pp. 165-174. https://doi.org/10.1016/j.mla.2009.05.005

Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF : A pilot study. / Vidyasagar, Mamidipudi Srinivasa; Kodali, Maheedhar; Balu, Prathima N.; Baijal, Gunjan; Vadhiraja, Bejadi Manjunath; Bhat, Rani A.; Fernandes, Donald Jerard; Krishna, Chilakapati Murali.

In: Medical Laser Application, Vol. 24, No. 3, 01.08.2009, p. 165-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum protein profile studies of cervical cancers in monitoring of tumor response to radiotherapy using HPLC-LIF

T2 - A pilot study

AU - Vidyasagar, Mamidipudi Srinivasa

AU - Kodali, Maheedhar

AU - Balu, Prathima N.

AU - Baijal, Gunjan

AU - Vadhiraja, Bejadi Manjunath

AU - Bhat, Rani A.

AU - Fernandes, Donald Jerard

AU - Krishna, Chilakapati Murali

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Objective: Exploration of the feasibility of serum protein profiles for monitoring tumor radioresponse in cervical cancers using HPLC-LIF system. Materials and methods: Twenty-one subjects were recruited in the study. Out of them 7 were healthy, 14 were cervical cancer patients who undertook fractionated radiotherapy (RT) with 2 Gy per fraction over 25 fractions, for 5 weeks followed by 2 applications of intracavitary brachytherapy once a week. Blood collected from above subjects was processed to obtain serum. Serum chromatograms of 'normal' (n=7) and conspicuous probes before RT (n=14, 'malignant') and 24 h after second fraction of RT (n=13, '2-RT'), were recorded using an In-house-built HPLC-LIF set-up. Data were analyzed in two approaches: (1) classical method using relative intensities of selected peaks, (2) principal component analysis (PCA). Clinical assessment of tumor radioresponse was carried out 4 months after first fraction of RT and the degree of the tumor shrinkage was determined as an index of radioresponsiveness (complete response (CR): 100% shrinkage, partial response (PR): ≥50% shrinkage, and no response (NR): ≤50% shrinkage) which was further correlated with the analysis of 2-RT serum chromatograms. Results: Normal vs. malignant chromatograms demonstrated pronounced differences in the 800-1800 s region. Malignant vs. 2-RT chromatograms showed minute variations in the 1300-1800 s region. Our analysis, in both of the approaches, produced clear differentiation between 'normal' and 'malignant', whereas differentiation between 'malignant' and '2-RT' was minimal. Clinical evaluation of the tumor radioresponse yielded that out of 13 patients (one patient discontinued the radiotherapy) ten showed CR, two showed PR and one NR. In case of prediction of tumor radioresponse, analysis of the 2-RT chromatograms produced only minor differentiation among CR, PR and NR groups. Conclusion: Protein profiling of serum samples differentiated 'normal' from 'malignant', but could not differentiate 'malignant' from '2-RT'. Also this technique has limited application in prediction of tumor radioresponse.

AB - Objective: Exploration of the feasibility of serum protein profiles for monitoring tumor radioresponse in cervical cancers using HPLC-LIF system. Materials and methods: Twenty-one subjects were recruited in the study. Out of them 7 were healthy, 14 were cervical cancer patients who undertook fractionated radiotherapy (RT) with 2 Gy per fraction over 25 fractions, for 5 weeks followed by 2 applications of intracavitary brachytherapy once a week. Blood collected from above subjects was processed to obtain serum. Serum chromatograms of 'normal' (n=7) and conspicuous probes before RT (n=14, 'malignant') and 24 h after second fraction of RT (n=13, '2-RT'), were recorded using an In-house-built HPLC-LIF set-up. Data were analyzed in two approaches: (1) classical method using relative intensities of selected peaks, (2) principal component analysis (PCA). Clinical assessment of tumor radioresponse was carried out 4 months after first fraction of RT and the degree of the tumor shrinkage was determined as an index of radioresponsiveness (complete response (CR): 100% shrinkage, partial response (PR): ≥50% shrinkage, and no response (NR): ≤50% shrinkage) which was further correlated with the analysis of 2-RT serum chromatograms. Results: Normal vs. malignant chromatograms demonstrated pronounced differences in the 800-1800 s region. Malignant vs. 2-RT chromatograms showed minute variations in the 1300-1800 s region. Our analysis, in both of the approaches, produced clear differentiation between 'normal' and 'malignant', whereas differentiation between 'malignant' and '2-RT' was minimal. Clinical evaluation of the tumor radioresponse yielded that out of 13 patients (one patient discontinued the radiotherapy) ten showed CR, two showed PR and one NR. In case of prediction of tumor radioresponse, analysis of the 2-RT chromatograms produced only minor differentiation among CR, PR and NR groups. Conclusion: Protein profiling of serum samples differentiated 'normal' from 'malignant', but could not differentiate 'malignant' from '2-RT'. Also this technique has limited application in prediction of tumor radioresponse.

UR - http://www.scopus.com/inward/record.url?scp=67650090491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650090491&partnerID=8YFLogxK

U2 - 10.1016/j.mla.2009.05.005

DO - 10.1016/j.mla.2009.05.005

M3 - Article

VL - 24

SP - 165

EP - 174

JO - Medical Photonics

JF - Medical Photonics

SN - 1615-1615

IS - 3

ER -